Chemomab Therapeutics Ltd. (CMMB) Financial Statements (2026 and earlier)

Company Profile

Business Address KIRYAT ATIDIM, BUILDING 7
TEL AVIV, 6158002
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,519,00010,741,0009,883,00013,827,00015,186,00037,744,000
Cash and cash equivalent13,519,00010,741,0009,883,00013,827,00015,186,00037,744,000
Restricted cash and investments77,000     
Prepaid expense 1,307,000   1,348,000 
Deposits current assets26,374,00035,725,00041,841,00043,579,00045,975,00026,524,000
Other undisclosed current assets459,0002,259,0003,106,0001,934,000179,0001,574,000
Total current assets:41,736,00048,725,00054,830,00059,340,00062,688,00065,842,000
Noncurrent Assets
Operating lease, right-of-use asset227,000261,000295,000309,000345,000359,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization367,000380,000355,000358,000357,000234,000
Prepaid expense733,000776,000821,000864,000908,000952,000
Restricted cash and investments  77,00077,00085,00055,00053,000
Total noncurrent assets:1,327,0001,494,0001,548,0001,616,0001,665,0001,598,000
TOTAL ASSETS:43,063,00050,219,00056,378,00060,956,00064,353,00067,440,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,066,0005,351,0004,262,0003,401,0002,544,0001,569,000
Employee-related liabilities1,527,0001,117,000666,000653,000451,000
Accounts payable1,688,0001,247,0001,433,0001,487,0001,336,000481,000
Accrued liabilities3,378,0002,577,0001,712,0001,248,000555,000637,000
Other undisclosed current liabilities1,683,000126,000132,000116,000106,00061,000
Total current liabilities:6,749,0005,477,0004,394,0003,517,0002,650,0001,630,000
Noncurrent Liabilities
Long-term debt and lease obligation:  118,000148,000203,000237,000298,000
Liabilities, other than long-term debt91,000     
Operating lease, liability91,000118,000148,000203,000237,000298,000
Other undisclosed noncurrent liabilities  (118,000)(148,000)(203,000) (298,000)
Total noncurrent liabilities:91,000118,000148,000203,000237,000298,000
Total liabilities:6,840,0005,595,0004,542,0003,720,0002,887,0001,928,000
Equity
Equity, attributable to parent36,223,00044,624,00051,836,00057,236,00061,466,00065,512,000
Treasury stock, value(1,218,000)     
Additional paid in capital101,260,000100,171,00099,303,00098,513,00097,639,00096,649,000
Accumulated deficit(63,819,000)(55,547,000)(47,467,000)(41,277,000)(36,173,000)(31,137,000)
Total equity:36,223,00044,624,00051,836,00057,236,00061,466,00065,512,000
TOTAL LIABILITIES AND EQUITY:43,063,00050,219,00056,378,00060,956,00064,353,00067,440,000

Income Statement (P&L) (USD)

3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
Operating expenses(8,642,000)(8,317,000)(6,254,000)(5,320,000)(5,024,000)(2,891,000)
Other undisclosed operating loss (5,142,000)   (3,310,000) 
Operating loss:(13,784,000)(8,317,000)(6,254,000)(5,320,000)(8,334,000)(2,891,000)
Other undisclosed income from continuing operations before equity method investments, income taxes 353,000     
Loss from continuing operations before equity method investments, income taxes:(13,431,000)(8,317,000)(6,254,000)(5,320,000)(8,334,000)(2,891,000)
Other undisclosed income (loss) from continuing operations before income taxes5,169,000237,000(480,000) 28,155,000 
Income (loss) from continuing operations before income taxes:(8,262,000)(8,080,000)(6,734,000)(5,320,000)19,821,000(2,891,000)
Income tax expense (benefit)(10,000) 544,000   
Income (loss) from continuing operations:(8,272,000)(8,080,000)(6,190,000)(5,320,000)19,821,000(2,891,000)
Income (loss) before gain (loss) on sale of properties:(8,080,000)(6,190,000)(5,320,000)19,821,000(2,891,000)
Other undisclosed net income (loss)    216,000(24,857,000) 
Net loss:(8,272,000)(8,080,000)(6,190,000)(5,104,000)(5,036,000)(2,891,000)
Other undisclosed net loss attributable to parent      (77,000)
Net loss available to common stockholders, diluted:(8,272,000)(8,080,000)(6,190,000)(5,104,000)(5,036,000)(2,968,000)

Comprehensive Income (USD)

3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
Net loss:(8,272,000)(8,080,000)(6,190,000)(5,104,000)(5,036,000)(2,891,000)
Comprehensive loss, net of tax, attributable to parent:(8,272,000)(8,080,000)(6,190,000)(5,104,000)(5,036,000)(2,891,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: